SCHEMBL12097003

SCHEMBL12097003

CCOC(=O)c1csc(C(O)c2c(C)c3cc(C(F)(F)F)ccc3n2S(=O)(=O)c2cccc(C(C)(C)C)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 1/20 0.39
▸ PPARG P37231 4/20 0.37
▸ PPARA Q07869 4/20 0.37
▸ PPARD Q03181 3/20 0.37
▸ PTPRB P23467 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ GAA P10253 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ APP P05067 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ABCB1 P08183 1/20 0.35
▸ RORC P51449 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27936061 0.85 MAPT (0.36) HIF1APPARGPPARAPTPRBMAPT
SCHEMBL12096843 0.84 HIF1A (0.41) HIF1APPARGPPARAPPARDMAPT
SCHEMBL12096587 0.79 PPARG (0.47) HIF1APPARGPPARAPPARDMAPT
SCHEMBL12096669 0.77 CYP3A4 (0.38) HIF1APPARGPPARAPPARDCYP3A4
SCHEMBL12096646 0.76 CYP3A4 (0.39) PPARGPPARAPPARDCYP3A4CYP2D6
SCHEMBL12096622 0.75 GALK1 (0.40) PPARGPPARAPPARDCYP3A4CYP2D6
SCHEMBL12096702 0.74 PTGER1 (0.43) PPARGPPARAPPARDMAPTCYP3A4
SCHEMBL28947331 0.71 MAPT (0.36) HIF1AMAPTGAAKDM4EAPP
SCHEMBL12097004 0.69 CYP3A4 (0.40) HIF1APPARGPPARAPPARDCYP3A4
SCHEMBL12096905 0.68 PPARG (0.50) PPARGPPARAPPARDMAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease LABORATOIRES FOURNIER SA (FR) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease NCOR1, NR0B1, MTNR1A HIF1A 1357/4885PPARG 423/4885PPARA 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback